Acer therapeutics inc. (ACER)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-4,948

-5,156

-5,251

-11,041

-7,968

-8,496

-3,965

-4,835

-3,983

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-3,379

-2,135

-299

-2,104

-2,160

-2,377

-2,793

-3,496

-3,350

-3,355

-3,878

-4,163

-3,655

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense

-

-

-

-

-

-

-

-

-

0

120

109

13

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

667

661

564

715

671

386

352

326

252

281

105

14

15

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

145

-122

100

-44

-

-

-

-

Restricted stock expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

48

53

100

Depreciation

17

17

13

17

9

11

5

4

6

1

0

0

0

0

-135

65

72

71

89

94

96

96

97

98

95

Write-off of deferred financing costs

-

-

-

-

-

-

-

-

-

0

0

0

1

-

-

-

-

-

-

-

-

-

-

-

-

Option expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

188

153

-1,497

189

205

266

-

248

260

331

Changes in operating assets and liabilities
Prepaid expenses

-

-

-

-

-

-

-

-

-

-

338

281

-327

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

-182

-164

179

13

-296

-69

572

-255

-55

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-216

531

-1,509

1,477

-972

438

-265

535

229

-443

-486

177

464

200

101

24

-186

-278

-130

507

-61

330

-456

145

-12

Accrued expenses

-773

-210

-1,016

412

-1,787

2,986

-311

-281

215

226

-1,056

415

483

-79

-470

244

202

116

140

-372

73

-804

227

398

-4

Other non-current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-110

-98

977

-74

-279

-75

-118

-703

-116

425

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-726

-726

-726

-726

-726

2,622

1,102

-307

-307

-348

Other noncurrent assets

-

-

-

-

-

-13

-6

24

2

-

-

-

-

-

-

-

-

-506

-9

-9

-9

-

-

-

-

Net cash used in operating activities

-5,070

-3,991

-7,375

-8,389

-9,750

-4,590

-4,750

-4,019

-3,227

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-113

-4

-11

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-2,072

-2,383

-0

-2,028

-2,545

-3,479

-3,135

-3,487

-222

-3,689

-3,203

-3,393

-3,909

Purchase of property and equipment

-

52

-8

46

88

10

69

5

9

-

-

-

-

-

-

-

0

22

58

5

6

41

21

51

75

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-0

-0

-0

-22

-58

-5

-6

-41

-21

-51

-75

Net cash used in investing activities

-

-52

8

-46

-88

-10

-69

-5

-9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Common stock sold for cash net of offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Payment of deferred offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Note payable - insurance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

55

55

186

0

0

0

-

-

-

-

Costs associated with the issuance of common stock

-

-

-

-

-

-

-

0

38

-

-

-

-

-

-

22

27

0

0

-104

104

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

0

0

4

62

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from convertible notes payable

-

-

-

-

-

-

-

-

-

0

0

2,375

3,125

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

3,062

0

8,155

-78

-82

493

502

12,203

-104

0

648

0

0

Net cash provided by financing activities

-

-

-

-

-

87

42,662

0

-38

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-5,070

-

-

-

-9,839

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-4,024

-3,275

7,240

5,896

-314

989

-2,383

8,155

-2,108

-2,628

-3,008

-2,691

8,710

-333

-3,731

-2,577

-3,444

-3,985

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

0

0

0

0

Cash paid during the year for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

2

-0

0

0

1

0

0

0

Accretion of issuance costs on Series A Convertible Redeemable Preferred stock

-

-

-

-

-

-

-

-

-

0

44

3

3

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of issuance costs on Series B Convertible Redeemable Preferred stock

-

-

-

-

-

-

-

-

-

0

109

9

9

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid additions to property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

Unpaid deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

-

-

-

511

-

-

-

17